Total revenue of $6.3M Includes $3.3 Million of Product Revenue in Addition to a One-Time Upfront Payment of $3.0 Million in License Revenue from ...

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company dedicated to developing innovative therapies for unmet medical needs, today announced its collaboration with OnTargetx R&D Inc. to ...

Omeros Corporation today announced two presentations that will be featured at the 2025 Tandem Meetings ? the Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and ...

MACOM Technology Solutions Holdings, Inc. ( NASDAQ: MTSI) Q1 2025 Earnings Conference Call February 6, 2025 8:30 AM ET Steve Ferranti - VP of Corporate Development and IR Steve Daly - President and ...

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company", "Sona") is pleased to announce that its recently published findings from its "Targeted Intra-tumoral Hyperthermia with Uniquely ...

THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU)Company initiating process to leverage ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...

Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that ...

The government is larger today than it was back then, so there was less interest on the part of the oligarchs of the day to ...